Research
Hormonal
Tirzepatide reduced incident obstructive sleep apnea (OSA) compared with liraglutide (0.89; 0.82–0.97) but not semaglutide (0.94; 0.86–1.02).
Tirzepatide may be beneficial in managing both diabetes and associated sleep apnea in patients.
StrongSupportsmedium confidence
Moreover, tirzepatide reduced incident OSA compared with liraglutide (0.89; 0.82–0.97) but not semaglutide (0.94; 0.86–1.02).
Why this rating
Based on a retrospective cohort analysis in a large global database.
Source
Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence
Alex E. Henney et al. · Annals of the American Thoracic Society · 2025
DOI 10.1513/annalsats.202409-923oc
cohort · n=15668Cited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →